CSF3 and Decreased total neutrophil count: Human GCSF (hGCSF) has been approved for the treatment of neutropenia, a common disorder in cancer patients following radiotherapy or chemotherapy treatments, characterized by an extremely low number of neutrophils in the blood [9], [10].